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Hippocampal processing is strongly implicated in both spatial cognition and anxiety and is temporally organized by the theta rhythm.
However, there has been little attempt to understand how each type of processing relates to the other in behaving animals, despite their
common substrate. In freelymoving rats, there is a broadly linear relationship between hippocampal theta frequency and running speed
over the normal range of speeds used during foraging. A recent model predicts that spatial-translation-related and arousal/anxiety-
relatedmechanismsofhippocampal thetagenerationunderliedissociable aspectsof the theta frequency–running speed relationship (the
slope and intercept, respectively). Here we provide the first confirmatory evidence: environmental novelty decreases slope, whereas
anxiolytic drugs reduce intercept. Variation in slope predicted changes in spatial representation by CA1 place cells and novelty-
responsive behavior. Variation in intercept predicted anxiety-like behavior. Our findings isolate and doubly dissociate two components
of theta generation that operate in parallel in behaving animals and link them to anxiolytic drug action, novelty, and the metric for
self-motion.
Introduction
The hippocampal formation is held to play key roles in two very
distinct brain functions: (1) context-dependent spatial and declara-
tive memory (O’Keefe and Nadel, 1978; Squire, 1992; Aggleton and
Brown, 1999; Eichenbaum, 2000), linked to novelty detection
(Hasselmo et al., 1996; Lisman and Grace, 2005); and (2) anxiety
(Gray and McNaughton, 2000; Kjelstrup et al., 2002; Bannerman
et al., 2004; Engin and Treit, 2007; Oler et al., 2010), linked to
stress/depression. The temporal organization of hippocampal
processing is dominated by the septohippocampal theta rhythm
of the local field potential (LFP) (Buzsa´ki, 2002; O’Keefe, 2006),
implicated in anxiety/anxiolytic-drug action (Gray, 1982; Gray
and McNaughton, 2000; Seidenbecher et al., 2003; Gordon et al.,
2005; Shin et al., 2009; Adhikari et al., 2010; Cornwell et al., 2012),
memory-related novelty processing (Hasselmo et al., 2002; Du¨zel
et al., 2010; Lever et al., 2010; Rutishauser et al., 2010), and spatial
cognition (Jones and Wilson, 2005; Buzsa´ki, 2006; O’Keefe, 2006;
Giocomo et al., 2007, 2011; Maurer and McNaughton, 2007;
Huxter et al., 2008; Brandon et al., 2011; Jezek et al., 2011; Koenig
et al., 2011).
Two mechanisms of theta generation have been identified: (1)
“movement-related” type I relating to translational movement;
and (2) “alert immobility-related” type II linked to arousal/anx-
iety (Kramis et al., 1975; Sainsbury et al., 1987; Buzsa´ki, 2002). A
recent model (Burgess, 2008) links these two mechanisms to dis-
sociable components of the relationship of theta frequency [f(t)]
to running speed [s(t)]:
f(t)  f0  s(t),
where the increase with running speed (, slope) reflects the
presence of “velocity-controlled oscillators” in the septohip-
pocampal system (Burgess, 2008; Welday et al., 2011): neurons
whose firing shows theta-band modulation whose frequency in-
creases with running speed, as seen in place (Geisler et al., 2007)
and grid (Jeewajee et al., 2008a) cells. This slope component is
identified with type I mechanisms in being movement related and
entorhinal cortex dependent (O’Keefe, 2006); the second com-
ponent ( f0, intercept) is identified with type II theta mechanisms
in being independent of both movement and entorhinal cortex
(Burgess, 2008, pp 1168 –1169). Thus, the model predicts a dis-
sociation between the factors affecting the intercept and slope of
the relationship of theta frequency to running speed. Although
work on theta typically focuses on theta power, two findings re-
late to these predictions for theta frequency.
All clinically effective anxiolytic drugs reduce average theta
frequency, despite their substantial neurochemical dissimilarities
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(Gray and McNaughton, 2000). In addition, immobility-related
type II theta occurs during predator-elicited arousal/anxiety
(Sainsbury et al., 1987) and during “anticipatory anxiety” (Gray
and McNaughton, 2000) after standard footshock conditioning
(Seidenbecher et al., 2003). Accordingly, because (1) arousal/
anxiety is explicitly linked to type II theta, (2) anxiolytics re-
duce reticular-elicited theta frequency, and (3) the Burgess
(2008) model links type II theta mechanisms to intercept, the
model predicts that anxiolytics should specifically reduce the
intercept f0.
Like anxiolytics, environmental novelty reduces average hip-
pocampal theta frequency (Jeewajee et al., 2008b). Because
Burgess (2008) relates slope () inversely to grid spatial scale
and grid scale increases in novelty (Barry et al., 2012), we pre-
dicted that novelty would specifically de-
crease the slope  of the frequency–speed
relationship.
Parts of this paper have been published




All subjects (experiment 1, n  4  2; experi-
ment 2, n 6; experiment 3, n 5; experiment
4, n 6) were individually housed male Lister
Hooded rats weighing 320 – 445 g at time of
surgery. Rats were chronically implanted with
microdrives in the hippocampus under deep
anesthesia and were given 1 week for postoper-
ative recovery, after which electrodes were low-
ered over several days/weeks. Rats were food
restricted from 1 week after surgery (target
was 85% of initial bodyweight). Rats foraged
for sweetened rice in the testing environments
and were placed on a holding platform between
trials in the same room as the testing environ-
ment. Across a given experiment, the first trials
of the day were begun at a similar time of day.
Trial durations were 10 min in experiments 1,
3, and 4, and 15 min in experiment 2. For ad-
ditional details of the experimental setup and
timelines, see Figure 1.
LFP data were recorded using an Axona data
acquisition system. All electrode wire was
heavy polyimide enamel-coated, 90% plati-
num–10% iridium (California Fine Wire). LFP
was recorded single ended from one electrode
tip of a 500 m separated stereotrode (i.e., ef-
fectively single electrode, 100 m diameter,
three of four rats in experiment 1) or of a te-
trode (25m diameter, one rat in experiment
1 and all rats in experiments 2 and 3; 17 m
diameter, plated, all rats in experiment 4).
LFP signals were amplified 2000 – 8000
times, bandpass filtered at 0.34 –125 Hz, and
sampled at 250 Hz. Two light-emitting diode
arrays attached to the head stage and viewed
by an overhead camera tracked head posi-
tion/orientation.
The LFP electrode sites for all rats in experi-
ments 1, 2, and 4 were confined to dorsal, an-
terior CA1 (3.0 – 4.6 mm posterior to
bregma). The LFP electrode site ranged from
stratum oriens to stratum lacunosum-molecu-
lare: no effect of layer on the results was seen.
The LFP electrode sites for experiment 3 (pri-
marily a reanalysis of novelty-exposure days in
the study by Jeewajee et al., 2008b) were in different regions in the dorsal
hippocampus: CA1 (two rats), subiculum (two rats), and dentate gyrus
(one rat).
Experiment-specific methods
Experiment 1: effects of anxiolytic drugs.The test environment was a black,
square-walled open-field environment (dimensions, 60  60  50cm)
with black Plexiglas flooring (65 65cm). The experiment lasted for 19 d
and consisted of four 4-d drug phases [in order: chlordiazepoxide hydro-
chloride (CDP); 1-(3-chlorophenyl)piperazine hydrochloride (mCPP);
FG7142; and buspirone hydrochloride] (for experimental timeline, see
Fig. 1a). Within each 4-d drug phase, days 1 and 3 were vehicle injection
days, and days 2 and 4 were drug injection days; each drug phase was
separated by a rest day. Having vehicle and drug injections on different
days permitted full accommodation of the half-lives of the drugs. Fur-
Figure 1. Experimental setup and timelines. a, Experiment 1 procedure. Intraperitoneal injections were given immediately
after the third trial of the day (V, vehicle; D, drug). n 4 rats. In addition, two additional drug-naive rats (rats 5 and 6) were
exposed to the testing environment of experiment 1 for 4 consecutive days and for five trials per day, with injections given
immediately after the fourth trial of the day (days 1–3, saline; day 4, buspirone). b, Experiment 2 procedure. n 6 rats. c,
Experiment 3 procedure. n 5 rats. d, Experiment 4 procedure. n 6 rats. Trials were 10 min in experiments 1, 3, and 4 and 15
min in experiment 2. ITIs ranged from 20 to 50 min. See Materials and Methods. FAM, Familiar; NOV, novel.
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thermore, the inclusion of rest days meant that there were 3 d between
the administration of different drugs, further permitting return to base-
line of any potential drug-related changes. Our focus was on drug effects
on theta around the time of their peak concentration in the brain. The
anxiolytic drugs CDP (a benzodiazepine agonist; Sigma-Aldrich) and
buspirone (a 5-HT1A agonist; Tocris Bioscience) and the anxiogenic drug
mCPP (a 5-HT2C agonist; Tocris Bioscience) were dissolved in a vehicle
of physiological saline. The anxiogenic drug FG7142 (a partial inverse
agonist; Tocris Bioscience) was suspended in saline containing Tween 80.
All drugs were administered intraperitoneally at a volume of 1 ml/kg.
Doses were as follows: CDP, 2.5 and 5 mg/kg; buspirone, 1 and 2 mg/kg;
mCPP, 0.5 and 1 mg/kg; and FG7142, 5 and 10 mg/kg (for a summary of
the literature that informed selection of the doses of CDP and buspirone,
see Table 1). Within each drug phase, days 1 and 3 were vehicle injection
days, and days 2 and 4 were drug injection days (lower and higher dose
order counterbalanced across rats). The intertrial interval (ITI) was 30
min. Immediately after trial 3 (the preinjection trial), the subject was
administered the vehicle/drug and placed on the holding platform until
trial 4 ( postinjection trial). Drug order was consistent across rats to
conform to two principles. The first principle was to use an anxiolytic
drug first, in case the effect of an anxiogenic drug was to elicit lasting
aversion to the testing environment. An extension of this principle was to
use the same anxiolytic drug in the first phase so that at least that anxio-
lytic drug could be tested on all four rats. In practice, there was no sign of
any lasting aversion. CDP was selected first because the anxiolytic effects
of benzodiazepines are very well established. The second principle was to
alternate transmitter systems (GABAergic, serotonergic). Because buspi-
rone was the last of the drugs administered in experiment 1, we tested the
effects of a single administration of the low dose (1 mg/kg) in two addi-
tional, drug-naive rats (rats 5 and 6) with CA1-implanted electrodes.
These rats were exposed to the testing environment of experiment 1 for 4
consecutive days and for five trials per day (same trial length and ITI).
Intraperitoneal injections were given immediately after trial 4 of the day
(days 1–3, saline; day 4, buspirone).
Within each drug phase, dose order (high vs low) was counterbalanced
across rats, with two rats experiencing drug stages in which the first
administrations of CDP and mCPP were the high dose, and the first
administration of FG7142 and buspirone were the low doses, with the
other two rats first receiving low doses of CDP and mCPP and high doses
of FG7142 and buspirone. Significant hypolocomotion occurred in three
mCPP trials, precluding robust analysis of this drug. ANOVA for drug
effects of the anxiogenic drug FG7142 showed no significant effects on
slope (F(2,6) 0.69, p 0.54) or intercept (F(2,6) 2.37, p 0.17), and
these results are not mentioned further. Although the doses of FG7142
used here were shown to be anxiogenic in rat models of anxiety (File and
Pellow, 1984; Cole et al., 1995), we cannot rule out the possibility that the
injections of FG7142 were not anxiogenic in our experiment.
Experiments 2–4: effects of environmental novelty. All experiments in-
volving environmental novelty (experiments 2– 4) shared the procedure
that the rat was placed into a novel environment that was centered on the
same position in the arena testing space (on a raised table) as the familiar
environment (Fig. 1b–d). In all experiments, the familiar environment
was a square-walled (60 60 or 62 62 cm) box with 50-cm-high walls.
The novel environments were of two types, which were similar across
experiments: (1) type A, which was a circular-walled box, with the wall
being 50 cm high; and (2) type B, which was a wall-less square platform.
Sets of visible cues external to the testing environments were also altered
between the familiar-environment and novel-environment configura-
tions. The diameter of the circular-walled box was as follows: 77 cm in
experiment 2; 79 cm in experiment 3; and 80 cm in experiment 4. The
sides of the wall-less square platform were as follows: 82  82 cm in
experiment 2; and 100 100 cm in experiment 4. Novelty-exposure days
involved trials in both the familiar and novel environments and occurred
after many exposures over several days to the familiar environment,
comprising at least 19 trials in experiment 2, 22 trials in experiment 3,
and 29 trials in experiment 4. These exposures involved being repeatedly
passively transported to and from the fixed locations of holding platform
and familiar environment, which may further engender expectation of
Table 1. Our doses of CDP and buspirone have been shown previously to be anxiolytic
Test Dose (mg/kg) References
Chlordiazepoxide
Elevated plus maze (anxiolytic increases proportion of open arm time) 2.5 Millan et al., 2001; Roy et al., 2009
5.0 Pellow et al., 1985; Gentsch et al., 1987; Chaouloff et al., 1997; Frussa-Filho et al., 1999;
Frussa-Filho and Ribeiro, 2002; Vendruscolo et al., 2003 ; Ramos et al., 2008; Roy et al.,
2009
Social interaction (anxiolytic increases social interaction time) 2.5 Vale and Montgomery, 1997
5.0 Baldwin and File, 1989; Vale and Montgomery, 1997; Millan et al., 2001; Haller and Bakos,
2002
Open field (anxiolytic increases center time, decreases defecation) 2.5 Angrini et al., 1998
3.0 Sanger and Zivkovic, 1988
3.5 Horváth et al., 1992
5 Gentsch et al., 1987; Horvarth et al., 1992
Geller–Seifter conflict test (anxiolytic increases punished responding) 2.0 Britton et al., 1997
4.0 Britton et al., 1997
5.6 Paterson and Hanania, 2010
Buspirone
Elevated T-maze (inhibitory avoidance task is time taken to leave the
enclosed arm on three consecutive trials; reduction in latency
compared with controls is anxiolytic)
1.0 Graeff et al., 1998; Poltronieri et al., 2003
3.0 Graeff et al., 1998; Poltronieri et al., 2003
Open field (anxiolytic increases center time, decreases defecation) 0.3 Stefa´nski et al., 1992; Siemiatkowski et al., 2000
3.0 Lim et al., 2008
Social interaction (anxiolytic increases social interaction time) 0.16 Dekeyne et al., 2000
0.63 Dekeyne et al., 2000
1.0 Costall et al., 1992
Contextual fear conditioning (anxiolytic reduces freezing duration) 0.3 Kakui et al., 2009
0.5 Wisłowska-Stanek et al., 2005
1.0 Wisłowska-Stanek et al., 2005 ; Kakui et al., 2009
2.0 Thompson and Rosen, 2006; Kakui et al., 2009
Inexperiment 1, CDPwas injected intraperitoneally at doses of 2.5 and5mg/kg, andbuspironewas injected intraperitoneally at doses of 1 and2mg/kg. The citations showthat thesedoseshaveproducedanxiolytic effects in previous studies.
8652 • J. Neurosci., May 15, 2013 • 33(20):8650–8667 Wells et al. • Two Components of Hippocampal Theta Rhythm
the familiar environment within the testing-room setting. Thus, at least
the very first exposures to novel environments present novelty that is
“unexpected.” ITIs were as follows: experiment 2, 20 –30 min; experi-
ment 3, 20 min; and experiment 4, 20 min (T1–T2 and T2–T3 intervals)
and 50 min (T3–T4 interval).
Slope and intercept data reported for experiment 2 were taken from
saline-injected trials in novel environments described above. Rats were
exposed to novel environments on days 5 or 11, with trials in familiar
environments on days 1– 4 and 7–10, with a rest day on day 6.
Experiment 3 examining novelty and refamiliarization reanalyzed the
novelty-exposure days in the study by Jeewajee et al. (2008b). Subjects
comprised the four rats 1– 4 reported in that study, and an additional rat
(rat 5) with good quality theta over days 1*–3*. As reported by Jeewajee et
al. (2008b), the test trial series for rat 1 was terminated at the end of day
1*, so ANOVA involving days 1*–3* exclude rat 1 but include rat 5 (thus,
four rats in total). The frequency of rearing on hindlegs was counted
using manual cell counters during each trial to index the behavioral
response to environmental novelty (Anderson et al., 2006; Lever et al.,
2006; Hunsaker et al., 2008).
For additional details of Experiment 4, see next section.
Experiment 4: effects of drug (O-2545) and environmental novelty. The
water-soluble cannabinoid CB1 receptor agonist O-2545 (Tocris Biosci-
ence) (Martin et al., 2006) was dissolved at 100 g/ml in a vehicle of
physiological (0.9%) saline. Intraperitoneal injections were administered
at a volume of 0.5 ml/kg. The dose was a “low” dose, which our pilot trials
had shown to minimally reduce locomotion (for experiment 4 timeline,
see Fig. 1e). The experiment consisted of two blocks of 5 d each, separated
by a rest day, with four trials per day: block A (days A1–A5) and block B
(days B1–B5). Trials 1, 2, and 3 occurred 90, 60, and 30 min before the
injection, respectively (T3 is the “preinjection trial”), whereas trial 4 (T4
is the “postinjection trial”) began 30 min after the injection. On days 1– 4
of each block, all trials were in the familiar environment. On day 5, the rat
was introduced to the novel environment in trial 4: either NovA (A
block) or NovB (B block). On days 1–2 of each block, vehicle was in-
jected, and on days 3–5, injections alternated between drug and vehicle in
a counterbalanced way across blocks and rats. Days 3– 4 of each block
provided the vehicle and drug data in a familiar environment, and day 5
provided the vehicle and drug data in a novel environment. For the 2
(vehicle, drug) 2 (familiar, novel) repeated-measures ANOVA, the two
T4 –T3 data points for each drug condition in the familiar environment
were averaged to provide one vehicle T4 –T3 value and one drug T4 –T3
value.
Thigmotaxis (“wall-hugging”) in novel walled environments, such as
the traditional open field and elevated plus/zero-maze tests, is a well-
established index of anxiety-like behavior in laboratory rodents. When
placed into such environments, intact rats and mice prefer to stay near
the walls, thereby avoiding the potentially dangerous open or “unpro-
tected” areas of the apparatus. An extensive literature confirms that thig-
motaxis (or open-area avoidance) is bidirectionally sensitive to a wide
range of anxiolytic and anxiogenic drugs, with anxiolytic drugs increas-
ing time spent in open, unprotected areas (Prut and Belzung, 2003; Rod-
gers, 2010).
Experiment 4: CA1 place cell recording and analyses. CA1 place cells
were recorded simultaneously with the LFP recording described above.
Tetrodes made from 17-m-diameter, heavy polyimide enamel-coated,
90% platinum–10% iridium electrode wire with plated tips were loaded
onto 16-channel microdrives, implanted above the dorsal hippocampus
of one or two hemispheres per rat, and gradually lowered into the CA1
pyramidal layer. Tetrode signals were amplified (15,000 –50,000) and
bandpass filtered (500 Hz to 7 kHz). Each channel was continuously
monitored at a sampling rate of 50 kHz, and action potentials were stored
as 50 points per channel (1 ms, with 200 s prethreshold and 800 s
postthreshold) whenever the signal from any of the four channels of a
tetrode exceeded a given threshold. Cluster cutting of CA1 spike data was
performed manually using custom-made software (TINT; Axona). Sin-
gle units were classified into putative pyramidal cells and interneurons on
the basis of the peak-to-trough interval of the mean waveform and the
mean interspike interval in the first 20 ms of the spike train autocorrelo-
gram (see Csicsvari et al., 1999). The inclusion criteria for pyramidal cells
were: peak-to-trough interval of at least 0.25 ms and mean interspike
interval (0 –20 ms)13 ms. The inclusion criteria for interneurons were:
peak-to-trough interval of0.25 ms and mean interspike interval (0 –20
ms) 9.5 ms. These criteria were used because they divided 681 units
effectively into two classes (558 pyramidal cells, 115 interneurons) with
only eight outliers.
Pyramidal cells were recorded during all four of the 2 (drug, vehicle)
2 (familiar, novel) conditions across trial 3 (preinjection baseline trial)
and trial 4 (postinjection probe trial) in six rats over 33 T3–T4 sessions.
For each rat, there were four T3–T4 sessions comparing trials in the
familiar environment and two T3–T4 sessions comparing trials in the
novel environment, with the exception that three sessions from block B
of rat 5 lacked pyramidal cell data.
Locational firing rate maps were constructed from 2.1  2.1 cm
binned data and smoothed using a 5  5 bin boxcar filter. Spike count
divided by dwell time gave firing rate per bin. To compare firing rate
maps from trials in different environments in the assessment of remap-
ping, corresponding bins in environments of different shape or size were
defined as those with the same direction from the center and proportion
of distance from the center to the edge along that direction, using
nearest-neighbor interpolation (Wills et al., 2005). The degree of spatial
remapping was assessed using the population vector method (Leutgeb et
al., 2005). This measures how similar the firing activity of the pyramidal
cell population is within each spatial bin across two trials. For each spatial
bin of the rate map, the rates of all place cells in that bin were correlated
across the two trials to give a Pearson’s correlation coefficient r. The
mean of the correlation coefficients across all bins was taken as the esti-
mate of the degree of remapping between the trials. When place cell
ensembles were recorded from two CA1 hemispheres, the population
vector was hemisphere weighted as follows. For NL cells from the left
hemisphere with mean vector value L and NR cells from the right hemi-
sphere with mean vector value R, the weighted population vector value
was (NLL NRR)/(NL NR). Firing rate maps shown in the figures are
autoscaled false color maps, with each color representing a 20% band of
peak firing rate, from dark blue (0 –20%) to red (80 –100%). Peak rate
(after smoothing) is the maximal firing rate in any bin.
Experiments 1, 2, and 4: measuring aural temperature. Aural tempera-
ture was measured using a Braun thermometer (experiments 1 and 2,
ThermoScan 4020; experiment 4, ThermoScan IRT4520). In experi-
ments 1 and 4, temperature was measured before (three times) and after
(three times) every trial for two of four rats (experiment 1) and four of six
rats (experiment 4). The highest value across the three measurements was
taken as the most reliable reading, and only this value was used. The
temperature for a given trial was the mean of the “before” and “after”
values. In experiment 2, aural temperature was measured three times
after every trial in all six rats, with the highest of the three measurements
being taken as the trial value. All rats were habituated to temperature
measurement in advance of the experimental phase.
Previous literature demonstrates that, although the absolute temper-
ature may differ somewhat across aural and brain sites, changes in aural
temperature closely parallel changes in brain temperature, whereas tem-
perature across brain regions is highly consistent. For example, Eshraghi
et al. (2005) assessed normothermia (37°C), mild (33°C), and moderate
(30°C) hypothermia and slow rewarming in anesthetized rats. They mea-
sured the temperature of the cochlea, brain, temporalis muscle, and rec-
tum. Cochlear and brain temperature were highly correlated during
induction of systematic hypothermia (r  0.91, p  0.001) and during
rewarming (p  0.89, p  0.001). Dunscombe et al. (1980) recorded
from the tympanic membrane (eardrum) while rats underwent brain
heating (to 41°C). They confirmed that measuring tympanic membrane
temperature could substitute for measuring intracranial temperature
(mean brain ear temperature0.1°C at 37°C and 41°C). Moser et al.
(1993) used thermistors to record hippocampal temperature in freely
moving rats, sometimes from opposite hemispheres. Bilateral activity-
induced temperature changes were nearly identical (0.15°C different).
Kiyatkin et al. (2002, p 165) measured temperature in the cerebellum and
dorsal and ventral striatum in freely moving rats exposed to a wide range
of stimuli. They reported that brain temperatures “differed slightly but
consistently between the regions sampled.”
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In summary, at least in the rat, ear and regional brain temperatures are
closely linked, and therefore measuring aural temperature provides a
reasonably accurate reflection of temperature in brain regions contrib-
uting to septohippocampal theta.
Relationship between LFP theta frequency and running speed
To characterize the dynamic relationship between theta frequency and
running speed, a cycle-by-cycle approach was used to estimate momen-
tary LFP frequencies. The recorded LFP signal was filtered using a 6 –12
Hz, 251-tap, Blackman windowed, bandpass sinc (sine cardinal) filter.
Windowing the filter achieves good stop-band attenuation and small
pass-band ripple. An analytic signal was then constructed using the Hil-
bert transform, taking the form Sa(tk) S(tk) iH[S(tk)], whereH is the
Hilbert transform, S(tk) is the filtered LFP signal, tk  k, where k 
1,..,K indexes the time step, and is the inverse of the sampling rate. The
phase of the analytic signal (tk) gives the phase of the LFP at tk, and the
difference in phase between each time point defines the frequency. Be-
cause the LFP sampling rate was five times that of position, instantaneous
frequency was averaged over every five consecutive values corresponding
to each position sample. Thus, concurrent measurements of speed and
LFP theta frequency were produced every 20 ms.
To quantify the linear relationship between theta frequency and speed
in a given trial, a regression line was fitted to the frequency–speed data
points for speeds between 5 and 30 cm/s, with each speed bin being 2.5
cm/s in width, thus creating 10 speed bins for each trial. Speeds below 5
cm/s were excluded to avoid non-theta behaviors, such as stopping or
sitting quietly. Speeds above 30 cm/s were excluded to avoid too few
samples in some trials and occasional tracking errors or head movements
producing apparent high speeds. The use of 10 narrow bins, within upper
and lower limits, minimizes any differences in mean speed per bin be-
tween trials containing different distributions of speed (see below).
Theta intercept was defined as the intercept of the regression line with
the y-axis (frequency) at 0 cm/s running speed, and theta slope was the
gradient of the regression line. These values were used for statistical
analyses. To best visualize these data across rats, we constructed plots of
the theta frequency–speed relationship as described below.
We analyzed a subset of the data to investigate the possibility that
drug-elicited changes in locomotion could systematically affect the aver-
age speed of the samples in the 10 matched bins in the 5–30 cm/s range.
Buspirone was the only anxiolytic drug that caused a significant reduc-
tion in running speed (see Results). We analyzed the datasets for all rats
1– 4 in experiment 1 for CDP and buspirone. The differences in average
speed between vehicle and drug conditions in the 10 matched bins in the
5–30 cm/s range were vanishingly small. The net difference in average
speed in drug versus vehicle trials in these 10 bins was0.00015 cm/s for
CDP and 0.033 cm/s for buspirone. These negligible values indicate
that our speed-matching procedure works very well, even when whole-
trial average speeds differ significantly.
We also analyzed these datasets to confirm that the 5–30 cm/s range is
representative of the locomotion in this foraging paradigm. We found
that the 5–30 cm/s range contains 79.4 	 1.6% of all behavior above 5
cm/s (n  48 trials, 12 per rat). In summary, our analysis approach
combines being representative of the data with excellent speed matching.
Statistics
For drug effects on slope and intercept (experiments 1 and 4), we calcu-
lated difference values between the preinjection and postinjection trial as
[postinjection value (trial 4)] minus [preinjection value (trial 3)] for
vehicle and drug. In experiment 1, one-tailed t testing (for intercept
reduction by anxiolytic drugs) was used to compare effects of vehicle
versus drug (buspirone and CDP) on intercept. With the reduction being
observed, t testing for intercept reduction by O-2545 in the subsequent
experiment 4 was one tailed, and the ANOVA for a main effect of inter-
cept reduction was unidirectional. All other t tests were two tailed, and all
other ANOVAs were nondirectional.
Plots of the theta frequency–speed relationship
The absolute value of theta frequency varies systematically between rats
and correlates with variables such as the rat’s age (Wills et al., 2010). To
display data across rats in the figures, we account for these differences
using a similar normalization principle for all summary plots of theta
frequency versus running speed. Normalization was not applied to data
for statistical analyses. A normalization value is calculated for each rat as
the mean theta frequency over the relevant baseline trials. In experiment
1 (see Fig. 3a–e), the normalization value is the mean of the pre-vehicle
and pre-drug trials. In experiments 2 and 3 (see Fig. 4, a and b–d, respec-
tively) the normalization value is the mean of the trials in the familiar
environment (i.e., trials 1, 2, 3, and 6 in experiment 2 and trials 1, 2, and
5 in experiment 3). In experiment 4, the normalization value is the mean
of the pre-vehicle trials for vehicle-administration manipulations (see
Fig. 6a,c) or the pre-drug trials for drug-administration manipulations
(see Fig. 6b,d). The difference between each rat’s normalization value and
the mean normalization value over rats is then subtracted from each data
point shown. This removes any effects of differences in the mean theta
frequency over the relevant baseline trials across rats. In all plots, squares
show the average over rats, and error bars are SEM. Each rat contributes
one value to each speed bin in the range 5–30 cm/s, with that value being
an average of the many data points for that bin. The size of each speed bin
is 2.5 cm/s. Each rat contributes one value for intercept and one for slope,
derived directly from the regression analysis.
Results
We tested our predictions (dissociation of the slope and intercept
of the theta frequency–running speed relationship, with anxiolyt-
ics reducing intercept, novelty reducing slope) by recording nat-
urally occurring hippocampal theta from rats freely foraging for
scattered food rewards in open-field environments.
Anxiolytic drugs reduce the intercept of the theta
frequency–running speed relationship
The effects of two clinically well-established but neurochemically
dissimilar anxiolytics, buspirone (a 5-HT1A agonist) and CDP (a
benzodiazepine agonist), were tested in 4-d blocks (experiment
1). Four CA1-implanted rats experienced four trials daily for 4
consecutive days, receiving an intraperitoneal injection immedi-
ately after the third trial, of vehicle (days 1 and 3) or drug (days 2
and 4) (for experimental timeline, see Fig. 1a; for details of elec-
trode locations for experiment 1, see Fig. 2a–c, Table 2). We used
doses of buspirone and CDP shown previously to be anxiolytic in
rats in a wide range of anxiety models (Table 1). As predicted,
both anxiolytics significantly reduced the intercept of the fre-
quency–speed relationship (buspirone, F(2,6) 22.16, p 0.002,
Fig. 3a,b; CDP, F(2,6) 5.92, p 0.04, Fig. 3c,d) at both the higher
(paired t(3): buspirone, one-tailed p  0.004, 0.72 Hz mean re-
duction; CDP, one-tailed p 0.04, 0.36 Hz mean reduction) and
lower (paired t(3): buspirone, one-tailed p 0.02, 0.50 Hz mean
reduction; CDP, one-tailed p  0.05, 0.25 Hz mean reduction)
doses but had no effect on the slope (buspirone, F(2,6) 2.25, p
0.19; CDP, F(2,6) 0.39, p 0.70).
Buspirone was the final drug administered in experiment 1.
To confirm that intercept reduction was not somehow attribut-
able to previous injections, two additional, drug-naive rats (rats 5
and 6) with CA1-implanted electrodes were exposed to the test-
ing environment of experiment 1 for 4 consecutive days and for
five trials per day (same trial length and ITI). Intraperitoneal
injections were given immediately after the fourth trial of the day
(days 1–3, saline; day 4, buspirone). As predicted, buspirone re-
duced intercept (mean reduction of 0.39 Hz), a result that even
with just two rats approached significance (t(1)  4.08, Cohen’s
d 5.78, one-tailed p 0.076; Fig. 3e). Buspirone did not affect
slope (t(1) 0.22, p 0.86).
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Environmental novelty reduces the slope of the theta
frequency–speed relationship
Experiment 2 tested the effect of environmental novelty. Six CA1-
implanted rats experienced at least 4 d (four trials per day) in a
familiar environment and then on the novelty-exposure day ex-
perienced an identically centered novel environment (trials T4
and T5) between exposures to the familiar environment (trials
T1, T2, T3, and T6). Figure 4a shows that, as predicted, novelty
robustly reduced slope, without affecting intercept [slope, t(5)
5.2, p  0.003; intercept, t(5)  1.6, p  0.16; mean familiar
(T1–T3 and T6) vs mean novel (T4 and T5) trials].
The theta frequency–speed slope increases as a novel
environment becomes familiar
To confirm that slope reduction results from environmental nov-
elty per se and not intrinsic differences between environments,
experiment 3 tested whether subsequent familiarization to a
novel environment reverses the slope-reduction effect. After re-
peated exposures (four trials per day for 5 d) to a familiar envi-
ronment, five rats received 3 d of novelty exposure (day 1*, day
2*, and day 3*), each separated by a rest day. On these novelty
exposure days, rats experienced an identically centered novel en-
vironment (trials T3 and T4) between trials in the familiar
environment (trials T1, T2, and T5). As Figure 4b shows, expo-
sure to the novel environment dramatically flattened the slope of
the frequency–speed relationship, which then recovered over
days (Fig. 4c,d) as the initially novel environment became famil-
iar. This was confirmed by repeated-measures ANOVA of the
first two trials in each environment (Fam  T1, T2; Nov  T3,
T4) on each of the three novelty exposure days [environment
(novel, familiar) day (1, 2, 3) trial (1, 2)]; this showed a main
effect of environment (F(1,3) 22.68, p 0.018), a main effect of
day (F(2,6) 18.12, p 0.003), and a day environment inter-
action (F(2,6) 125.98, p 0.00001) on slope. In contrast, there
was no reliable effect on intercept (main effect of environment,
F(1,3) 3.22, p 0.17; main effect of day, F(2,6) 0.21, p 0.82;
day  environment interaction, F(2,6)  1.62, p  0.27). The
recovery of the slope suggests that there were no permanent ef-
fects or any intrinsic differences between the two environments.
There was also a main effect of trial on slope (F(1,3) 29.73, p
0.012) but not intercept (F(1,3) 0.07, p 0.81), consistent with
the observation that slope tends to increase on repeated within-
day exposures to the same environment.
Behavior was responsive to environmental novelty and
predicted by slope
Was our novelty manipulation behaviorally salient? To examine
this, we compared probebaseline (T3–T2) counts of rearing on
hindlegs on the last day of habituation (day 5, all trials familiar
environment) to those on the first day of environmental novelty
(day 1*, novel environment on T3 and T4). As observed in a
broadly similar study (Wells et al., 2009a), rats significantly in-
creased their rearing in response to environmental novelty. On
exposure to environmental novelty, rats greatly increased their
rearing frequency (mean net increase, novel vs familiar, 4.8	 0.5
rears/min, paired t(4)  8.9; Fig. 5a). Thus, rearing on hindlegs,
which is a hippocampus-dependent novelty-responsive behavior
(Lever et al., 2006), was highly sensitive to our environmental
novelty manipulation. The sharp reduction of slope in novelty
Figure2. LFP electrode tracks fromexperiments 1, 2, and4. Cresyl-violet-stained sections of
the dorsal hippocampus are shown for two rats (experiment 1, rats 1 and2). Arrows indicate the
trackof the LFPelectrode.a,b, Theprogressionof theelectrode track intoCA1 stratumradiatum
in rat 1.b shows theadjacent posterior section toa. c shows thebottomof electrode track in CA1
stratum radiatum of rat 2. d, e, Cresyl-violet-stained section of the dorsal hippocampus shown
for experiment 2, rat 2. Arrow indicates the bottom of the LFP electrode track (i.e., the most
medial) in stratum radiatum. e, Cresyl-violet-stained sections of the dorsal hippocampus are
shown for two rats (experiment 4, rats 4 and 6). Arrows indicate the track of the EEG electrode.
e shows the bottom of the LFP electrode track in CA1 stratum radiatum of rat 4. f shows the
bottom of the electrode track in CA1 stratum radiatum in rat 6. DG, Dentate gyrus.
Table 2. Electrode recording sites for experiments 1–4
Rat Location/layer
Experiment 1
1 CA1 stratum radiatum
2 CA1 stratum radiatum
3 CA1 lacunosummoleculare
4 CA1 stratum radiatum/lacunosummoleculare
Experiment 2
1 CA1 pyramidal layer/stratum radiatum
2 CA1 stratum radiatum
3 CA1 pyramidal layer/stratum radiatum
4 CA1 stratum radiatum
5 CA1 pyramidal layer/stratum radiatum
6 CA1 pyramidal layer/oriens
Experiment 3
1 CA1 stratum radiatum





1 CA1 stratum radiatum
2 CA1 stratum oriens
CA1 pyramidal layer/stratum radiatum
3 CA1 stratum radiatum
4 CA1 stratum radiatum
5 CA1 pyramidal layer/stratum oriens
6 CA1 pyramidal layer/stratum radiatum
CA1 stratum radiatum
For each experiment, table indicates estimated LFP electrode recording sites.Most electrodeswere in the pyramidal
layer and stratum radiatum of CA1.
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and its recovery with subsequent familiarization (Fig. 4b–d)
closely paralleled the sharp increase in rearing frequency (Fig. 5a)
and its habituation with subsequent familiarization (Fig. 5b,
slope reduction expressed as a positive magnitude). Indeed, the
rearing frequency in each of the four rats tested over the 3
novelty-exposure days was reliably predicted by the slope (Fig.
5c) but not the intercept (Fig. 5d; mean rearing vs slope, r 
0.73, p values0.02; for per-rat rearing vs slope and rearing vs
intercept values, see Table 3).
Within-subjects dissociation of effects on theta
frequency–speed slope and intercept
In separate experiments, anxiolytic drugs reduced intercept (ex-
periment 1), whereas environmental novelty reduced slope (ex-
periments 2 and 3). Experiment 4 combined the test for intercept
reduction and slope reduction within the same experiment while
targeting another neurotransmitter system to probe the general-
ity of anxiolytic intercept reduction (see Materials and Methods
and Fig. 1d). CB1 receptor agonists (especially at low doses) are
anxiolytic (Haller et al., 2004). Thus, we targeted the cannabinoid
system with a low systemic (intraperitoneal) dose of the novel
CB1 receptor agonist O-2545. As predicted, O-2545 alone specif-
ically reduced intercept (Fig. 6, a vs b; intercept, paired t(5) 4.8,
one-tailed p  0.002; slope, t(5)  0.2, p  0.87), whereas envi-
ronmental novelty alone specifically reduced slope (Fig. 6, a vs c;
slope, paired t(5) 6.9, p 0.001; intercept, t(5) 0.1, p 0.93),
and there was no interaction between the simultaneous effects of
O-2545 and novelty (Fig. 6a–d; drug: intercept, F(1,5)  13.70,
p 0.024; slope, p 0.83; environment: slope, F(1,5) 449, p
4  106; intercept, p  0.77; drug  environment: intercept,
p 0.60; slope, p 0.83). Thus, we demonstrate a double disso-
ciation, with independent modifiability of both the intercept-
related and slope-related theta components.
Reduction of theta slope between baseline and probe trials
predicted the degree of remapping in CA1 place cells and
place field size
In experiment 4, 558 CA1 place cells were recorded simultane-
ously with the CA1 LFP recordings from six rats over 33 sessions,
at an average of 16.9	 2.2 cells per session. We tested the predic-
tion (Burgess, 2008) that theta slope reduction contributes to
place cell remapping. Briefly, flatter slope expands grid scale, and
grid scale expansion should cause a mismatch between the grid
cell inputs to place cells and the environmental inputs mediated
by boundary cells in subiculum (Lever et al., 2009) and entorhinal
cortex (Solstad et al., 2008), which are unaffected by environ-
mental novelty (Lever et al., 2009). If theta slope controls remap-
ping (for quantification, see Materials and Methods), there
should be a correlation between, on the one hand, the change in
slope from the baseline trial (T3) to the probe trial (T4) and, on
the other hand, the similarity of spatial firing patterns across the
two trials. This prediction was confirmed (slope vs remapping,
n 33, r 0.72, p 0.000002; vehicle-only sessions, n 17, r
0.75, p 0.0005; drug-only sessions, n 16, r 0.69, p 0.003).
However, we cannot exclude the possibility that the slope is only
predicting remapping because novelty elicits slope reduction and
novelty elicits remapping.
An additional prediction from the model is that slope change
should predict changes in place field size. Because entorhinal grid
cells form an important input to place cells, any expansion in grid
scale in novelty (Barry et al., 2012) would be expected to increase
place field size, consistent with previous reports of novelty-
induced place field expansion (Karlsson and Frank, 2008; Barry et
al., 2012). We tested this prediction using place cells that fired
sufficiently robustly for field size measurement (120 spikes,
spatial peak rate1 Hz, n 360 total cells). As predicted, average
cumulative place field size (i.e., sum of areas of firing 20% of
peak rate) significantly increased in the novel environments
(main effect of novelty, F(1,4)  71.2, p  0.001; mean field size
change: familiar,8.2	 27 cm 2; novelty,967	 133 cm 2). The
increase in place field size appeared somewhat blunted by O-2545
(drug  novelty, F(1,4)  3.3, p  0.14), consistent with a CB1
receptor agonist-specific reduction of field size, shown previously
with a different CB1 agonist (Robbe and Buzsa´ki, 2009). Accord-
ingly, to better isolate the influence of slope on place field size, we
tested this relationship in vehicle and drug sessions separately
and together. As predicted, change in slope robustly predicted
change in average place field size in vehicle-only sessions (r
0.81, p 0.00009; n 17 sessions), drug-only sessions (r
0.73, p  0.001, n  16 sessions), and combined sessions
(r0.73, p 0.000001, n 33 sessions), indicating that the
result is robust. We acknowledge the caveat that our novel
environments were larger than the familiar environment, but
place field area typically expands much less than total environ-
mental area (Muller and Kubie, 1987; Fenton et al., 2008). The
familiar environment was approximately half the size (3844
cm 2) of the novel environments (average of 7513 cm 2: novel
A  5026 cm 2; novel B  10,000 cm 2). The novelty-elicited
Figure 3. Anxiolytic drugs reduce the intercept of the theta frequency–running-speed rela-
tionship; environmental novelty reduces its slope. Plots show theta frequency versus running
speed. a–d, Anxiolytic drugs (blue) reduce the 0 cm/s intercept of the frequency–speed rela-
tionship compared with control trials (gray/black) but has no significant effect on slope. Both
low and high doses are shown (buspirone: a, 1mg/kg and b, 2mg/kg; CDP: c, 2.5mg/kg and d,
5 mg/kg; all 1 ml/kg, i.p.; n 4 rats). See Experiment 1. e, Additional 1mg/kg buspirone-only
rats (n 2).
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mean increase of 967	 133 cm 2 that we
observed represents more than a dou-
bling in area; this is well in excess of an
increase in field area by a factor of only

2, which would be predicted by the
change in environmental size alone
(Muller and Kubie, 1987).
Does slope change or the novelty/fa-
miliarity of the probe environment best
predict changes in field size across base-
line and probe trials? To address this, we
averaged the two values from the two tri-
als in the familiar environment in each
condition (Fig. 1) so that each rat contrib-
uted an equal amount of data from the
familiar and novel probe sessions. (n 23
total sessions, comprising 2 (novel vs fa-
miliar)  2 (vehicle vs drug) conditions
for each of the six rats, minus one novelty-
under-drug condition lacking cells). To
take account of the novelty condition, we
divided field expansion in the novel envi-
ronments by
2 and assigned novelty sta-
tus value 1 and 2 for familiar and novel
environment probes, respectively. We
then performed partial correlation analy-
sis to test which of the two directional hy-
potheses had primacy: did slope reduction
or novelty status best predict field expan-
sion? As predicted by the model by Bur-
gess, 2008, slope change predicted field
size change controlling for the effect of
novelty status (r0.49, one-tailed p
0.01, n  23, df  20), whereas novelty
status did not predict changes in field size
controlling for the effect of slope (r 
0.11, one-tailed p  0.32) (results were
very similar for uncorrected field sizes).
Figure 7 shows the simple correlation
between change in slope and change in
field size (r  0.72, one-tailed p 
0.0001, n  23, slope reduction ex-
pressed as positive magnitude). In sum-
mary, novelty elicited field expansion,
and, moreover, the theoretically pre-
dicted relationship between slope and
field size change was observed.
O-2545 was anxiolytic, and theta
intercept predicted
anxiety-related behavior
A classic rodent test of anxiety mea-
sures the rodent’s thigmotaxis in a novel,
walled, open field. A voluminous litera-
ture shows that anxiolytic drugs increase
the time spent by rodents in the central
open area (see Materials and Methods).
Because the putative anxiolytic properties
of O-2545 have not been demonstrated,
we measured its effects in the walled novel
environment probe trial (T4, novel type
A; three rats saline, three rats O-2545).
As predicted for an anxiolytic, O-2545
Figure 4. Environmental novelty reduces theta slope,which recovers as the novel environment becomes familiar (experiments
2 and 3). a, Environmental novelty (red, pink) reduces frequency–speed slope; see experiment 2. Absolute frequency values are
normalized across rats. Squares,mean across rats; dashed lines, linear regression. Error bars are SEM. For details, seeMaterials and
Methods. Plots show theta frequency versus running speed. b, The first exposures to a novel environment in experiment 3 (trial 3,
red; trial 4, pink) on the first novelty day elicits a dramatic reduction in slope comparedwith exposure to the familiar environment
(trial 1, black; trial 2, dark gray; trial 5, light gray). Slope increases as the initially novel environment becomes more familiar on
subsequent days (c, day 2*; d, day 3*); see experiment 3. Conventions as in Figure 3. In both experiments 2 and 3, the same novel
environment is experienced twice (experiment 2, trials 4 and 5; experiment 3, trials 3 and 4).
Figure 5. Exploratory behavior (rearing) elicited by environmental novelty is predicted by theta slope (experiment 3). The first
exposure to a novel environment on the first novelty day (experiment 3) elicits a dramatic increase in rearing frequency (a). Probe
trial (T3) baseline trial (T2) values shown for FAM3 FAM on day 5 and FAM3 NOVEL on the next day, day 1*. b, Rearing
frequency parallels slope reduction over the 3 novelty days (see Fig. 4b–d and experiment 3). For ease of comparison, slope
reduction is shownas positive inmagnitude [i.e.,(T3–T2)]. c,d, Rearing frequency over 3 novelty days is reliably correlatedwith
slope (c) but not intercept (d).
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significantly increased the proportion of time that rats spent in
the central area in the novel probe trial (Fig. 8a,b). Moreover,
as predicted by the identification of intercept-related mecha-
nisms with arousal/anxiety, the intercept predicted thig-
motaxis. The absolute level of the intercept predicted the
absolute center time in the novel probe trial (T4 intercept vs
T4 center time, r  0.87, p  0.02, n  6; Fig. 8c), and the
change in intercept predicted the change in center time
(T4 –T3 intercept vs T4 –T3 center time, r0.83, p 0.04).
Lower intercept values were associated with lower anxiety,
that is, higher occupation of the central region. (The absolute
levels of occupation of the central region are of course much
higher than in the novel open-field paradigms typical in anx-
iety screening, but our rats are extensively handled and have
run many trials in the testing room.)
In summary, in addition to showing in experiment 1 that
well-established anxiolytic drugs reduce intercept, we identified a
novel drug as putatively anxiolytic and then showed that it too
reduces intercept and has anxiolytic effects behaviorally. We also
found suggestive evidence, albeit across vehicle and drug condi-
tions in a small sample (n 6), for a positive correlation between
intercept and anxiety-like behavior. The positive relationship be-
tween intercept and behavioral anxiety should be tested in other
paradigms with a larger sample.
Theta power is unaffected by anxiolytic drugs but can
increase in novel environments
We had no a priori model-based predictions regarding theta
power but tested for theta power changes elicited by the anxio-
lytic drugs and environmental novelty. To control for differing
behavior across conditions, we calculated peak theta power based
on subsets of data from each trial, chosen such that median run-
ning speed was constant in the data from each trial for a given rat.
There was no effect of either the anxiolytic drugs (CDP and bu-
spirone) or the putative anxiolytic drug (O-2545) on peak theta
power (experiment 1: main effect of drug, CDP, F(2,6) 0.07, p
0.93; buspirone, F(2,6)  1.08, p  0.40; experiment 4: O-2545,
drug (T4) baseline (T3) vs vehicle (T4) baseline (T3), t(5)
0.03, p 0.98). Theta power is often reported to increase under
novelty; however, previous work has typically failed to control for
the different behavior accompanying the response to novelty (see
discussion by Lever et al., 2009). To test the effects of environ-
mental novelty with increased statistical power, results from ex-
periments 2 and 4 were pooled and the baseline trial compared
with its immediately following novel environment trial (n 12,
all CA1, drug-free, T3 vs T4). The results showed that, overall,
theta power increased under novelty, but this was not reliable
(baseline, 0.65 	 0.10  106 V 2/Hz; novelty, 0.75 	 0.13 
106 V 2/Hz, paired t(11) 1.5, p 0.16). In fact, closer inspec-
tion showed that theta power increased significantly in the nov-
elty of experiment 2 (baseline, 0.69 	 0.11  106 V 2/Hz;
novelty, 0.86	 0.16 106 V 2/Hz, paired t(11) 2.7, p 0.04)
but negligibly in the novelty of experiment 4 (baseline, 0.62 	
0.18 106 V 2/Hz; novelty, 0.65	 0.20 106 V 2/Hz, paired
t(11)  0.3, p  0.78). The pooled analysis also confirmed that
environmental novelty reliably and specifically reduced slope
(slope baseline, 2.14	 0.15 Hz  m1  s1; slope novelty, 0.97	
0.13 Hz  m1  s1, paired t(11)  6.4, p  0.00005; intercept
baseline, 8.56 	 0.07 Hz; intercept novelty, 8.45 	 0.07 Hz,
paired t(11)  0.6, p  0.13). In summary, our results indicate a
dissociation in the effect of environmental novelty on theta
power and frequency: power shows a variable increase, whereas
frequency (slope) shows a reliable decrease.
Intercept as a physiological measure: intercept reduction
cannot be predicted from the firing rates of CA1 pyramidal
cells and interneurons
We have shown that the intercept of the hippocampal theta fre-
quency–running speed relationship is an important physiological
measure. Intercept reduction is common to three anxiety-
reducing drugs tested in our study and appears to predict anxiety-
like behavior. However, to what extent is intercept predictable
from other variables? Do anxiolytic drugs set hippocampal exci-
tation–inhibition dynamics toward a mode of inhibition whose
global physiological signature is the reduction of the theta fre-
quency–speed intercept, or do they share another effect for which
intercept reduction is only a useful proxy? We have shown that
CDP, buspirone, and O-2545 reduce intercept without changing
slope or theta power. Here we demonstrate that O-2545 does not
reliably affect firing rates of CA1 pyramidal cells and interneu-
rons. In experiment 4, 115 interneurons and 558 CA1 pyramidal
cells were recorded simultaneously with the CA1 LFP recordings.
Interneuron firing rate did not increase after injection of the
putative anxiolytic drug O-2545 (e.g., in familiar environment,
mean rate in preinjection and postinjection trials, 10.9 and 10.8
Figure 6. Within-subjects dissociation of anxiolytic and novelty effects on theta-speed in-
tercept and slope (experiment 4). Plots show theta frequency versus running speed in the
various conditions of experiment 4 (n  6 rats). a, b, Putative anxiolytic cannabinoid CB1
receptor agonist (O-2545) reduces intercept. a, c, Environmental novelty reduces its slope.
Simultaneous drug and novelty reduces both intercept and slope independently (a, d). O-2545
dose: 100g/ml, 0.5 ml/kg intraperitoneally. Conventions as in Figures 3 and 4. pre-inj, Pre-
injection; fam, familiar; nov, novel.
Table 3. Slope but not intercept predicted novelty-responsive behavior
Rears versus slope Rears versus intercept
Rat r value p value r value p value
5 0.584* 0.022* 0.003 0.991
2 0.810* 0.0002* 0.525* 0.045*
3 0.791* 0.0004* 0.499 0.058
4 0.754* 0.001* 0.305 0.269
In experiment 3, rears per trial was reliably predicted by the slope (mean r value across 4 rats0.73, p values
0.02), but not the intercept, of the theta frequency–speed relationship across the3dof combinedexposure to the
familiar environment and novel environment. For each correlation test, n 15 (3 d 5 trials/d). The 3 d of testing
are the novelty-exposure days 1*–3* of experiment 3, with 3 trials/d in familiar environment and 2 trials/d in novel
environment. *p 0.05, statistically significant correlations.
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Hz, respectively). For each of the five rats from which interneu-
rons were recorded in all of the 2 (drug, vehicle)  2 (novel,
familiar) conditions, we averaged firing rates over all interneu-
rons such that each rat contributed one value to each of the four
conditions. There was no main effect of drug (F(1,4)  0.2, p 
0.67) or interaction between drug and novelty (F(1,4)  0.7,
p 0.45).
The firing rate of putative pyramidal cells did not decrease
after injection of the putative anxiolytic drug O-2545 (e.g., in
familiar environment, mean rate in preinjection and postinjec-
tion trials, 0.6 and 0.6 Hz, respectively). For each of the five rats
from which pyramidal cells were recorded in all of the 2 (drug,
vehicle) 2 (novel, familiar) conditions, we averaged firing rates
over all pyramidal cells such that each rat contributed one value
to each of the four conditions. There was no main effect of drug
(F(1,4) 2.9, p 0.17) or interaction between drug and novelty
(F(1,4) 3.0, p 0.16). Similar results were seen when restricting
analysis to pyramidal cells that fired with a spatial peak rate of at
least 1.0 Hz in both the baseline and probe trials: there was no
main effect of drug (F(1,4) 3.3, p 0.15) or interaction between
drug and novelty (F(1,4) 3.6, p 0.13). Together, these results
argue for the singular utility of intercept as a physiological mea-
sure and for the apparently unique utility of intercept reduction
as a physiological signature of the effectiveness of an anxiolytic
drug.
Confirmatory analyses: intercept reduction by anxiolytic
drugs was not a secondary consequence of changes in cranial
temperature
Previous studies have indicated a positive relationship be-
tween temperature and theta frequency (Whishaw and
Vanderwolf, 1971; Deboer, 2002). We measured aural temper-
ature in a subset of eight rats (experiment 1, two of four rats in
the main study and the two rats administered buspirone only;
experiment 4, four of six rats) to ask how temperature affected
the intercept and slope of the theta frequency–speed relation-
ship in non-drug conditions and
whether these were affected by anxio-
lytic drugs. We conclude that the
intercept-reducing properties of the anxi-
olytic drugs cannot be attributed to sec-
ondary effects of temperature because (1)
temperature does not affect intercept, al-
though it does affect slope, (2) tempera-
ture was reduced by buspirone and
O-2545 but not by CDP, and (3) correct-
ing for temperature reduction showed
that intercept was still reliably reduced by
anxiolytic drugs. These three findings are
addressed below.
Importantly, there was no sign that the
measurement process itself increased
temperature in the rats. Over the anxio-
lytic drug phases of experiment 1 and all
of experiment 4, the average difference
between the first and last measurement
was0.008	 0.02°C.
Temperature showed no relationship to
intercept but was positively correlated
with slope
We examined the relationship between
temperature and slope and intercept in
drug-free conditions and found no significant correlation be-
tween temperature and intercept in any of the eight rats, whereas
slope and temperature were significantly positively correlated in
seven of eight rats. In experiment 1 (rats 3 and 4), we analyzed all
the preinjection trials (trials 1–3) on all 16 test days (n  48).
There was no correlation between temperature and intercept in
either rat (rat 3, r0.23, p 0.13; rat 4, r 0.21, p 0.15). In
contrast, temperature and slope were positively correlated in
both rats (Fig. 9a,b; rat 3, r 0.38, p 0.01; rat 4, r 0.68, p
0.01). In experiment 1 (rats 5 and 6), we analyzed all preinjection
trials (n 16, trials 1– 4, days 1– 4) and found that there was no





















Figure 7. Change in theta slope between baseline and probe trials predicts change in
place field size across those trials in CA1 place cells (experiment 4). Scatter plot showing
the change in theta slope versus change in place field size. Reduction in theta slope is
expressed as positive in magnitude [i.e.,(T4 –T3)]. Familiar environment probe trials
are shown as blue diamonds, and novel environment probe trials are shown as red
squares. Field size is average place field size of all cells firing120 spikes, the place field
of each cell is defined as the sum of all bins with firing at20% of peak rate. Field size
expansion values in novel environments are corrected by dividing by
2 (i.e., the in-
crease expected because of the larger novel environment).
Figure 8. Anxiety-related behavior (thigmotaxis) is increased by the putative anxiolytic O-2545 and predicted by theta inter-
cept (experiment 4). a, Dwell time maps showing where rats spent their time in the novel walled open-field probe trial (T4,
circular-walled novel environment) after injection with O-2545 (3 rats, maps 1–3) and vehicle (3 rats, maps 4–6). Rats injected
with O-2545 showed less thigmotaxis, i.e., spentmore time in the center, indicating anxiolysis. Dwell time is indicated by color (10
equal bands: dark blue bins, least time; red bins, most time, occupied by the rat for1.5 s). White squares denote unvisited bins.
b, O-2545 injection produced significantly less thigmotaxis than vehicle injection (Veh). *t(4) 2.79, p 0.05, O-2545 versus
vehicle, T4–T3 center time percentage. c, Theta intercept predicts anxiety-related behavior in the novel walled open field. Scatter
plot shows occupancy of central area versus intercept value. Numbers refer to dwell time maps shown in a.
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r 0.18, p 0.49; rat 6, r 0.17, p 0.52). In contrast, again,
temperature and slope were positively correlated in both rats
(Fig. 9c,d; rat 5, r 0.51, p 0.04; rat 6, r 0.58, p 0.02).
In experiment 4, we used all three preinjection trials on both
sets of 5 d blocks [rat 5, n 30; rats 2 and 6, n 24 because two
familiarization days (A1, A2) were excluded as a result technical
issues; rat 3, n 27 because 1 d (B5) was excluded as a result of
missing temperature data]. There was no correlation between
temperature and intercept in any of the rats (rat 2, r0.16, p
0.47; rat 3, r0.35, p 0.07; rat 5, r0.36, p 0.054; rat 6,
r  0.21, p  0.32). In contrast, again, temperature and slope
were significantly positively correlated in three of four rats (rat 2,
r 0.23, p 0.28; rat 3, r 0.40, p 0.04; rat 5, r 0.50, p
0.01; rat 6, r 0.43, p 0.04; Fig. 9e–g).
Temperature was reduced by buspirone and O-2545 but not
by CDP
The data were analyzed in the same way that we analyzed drug effects
on slope and intercept. We compared the difference values (postin-
jection temperature preinjection temperature) on the drug days
(regardless of dose) to those of vehicle days. This gave net tempera-
ture changes resulting from drug administration. In experiment 1
(rats 1–4), there was no evidence of temperature reduction by CDP
in either rat (mean net change: rat 3, 0.3°C; rat 4, 0°C). Buspirone
appeared to mildly reduce temperature in both rats 3 and 4 (mean
net change: rat 3,0.1°C; rat 4,0.4°C) and in the two drug-naive
rats (mean net change: rat 5,0.25°C; rat 6,0.6°C). In experiment
4, O-2545 reduced aural temperature in all temperature-measured
rats (net temperature change in familiar: rat 2, 0.32°C; rat 3,
0.27°C; rat 5,0.27°C; rat 6,0.43°C).
Correcting for temperature reduction showed that intercept
was still reliably reduced by anxiolytic drugs
Although temperature and intercept were not significantly cor-
related in any of the rats, the linear effects of temperature on
intercept were subtracted from the raw intercept values, and
these corrected values were retested. In experiment 1 (rats 1– 4),
the relationships between aural temperature and intercept in the
two temperature-measured rats in experiment 1 were similarly
weak and opposite in sign (rat 3, r  0.23, p  0.13; rat 4,
r  0.21, p  0.15). Raw intercept values were not temperature
corrected in analyses of the effect of drug. The temperature-
corrected results for rats 5 and 6 (mean change,0.36 Hz, t(1)
3.18, one-tailed p 0.097) were similar to the uncorrected results
(mean change,0.39 Hz, t(1) 4.08, one-tailed p 0.076).
To run temperature-corrected analyses for comparison with
the original dataset from experiment 4 (rat n 6), we estimated
corrected values for the two temperature-unmeasured rats from
averaged data in the four temperature-measured rats. From these
four rats (individual results above), we obtained the average tem-
perature change for each condition and the averaged linear rela-
tionship between temperature and intercept. Then, for each of
the two temperature-unmeasured rats, we corrected raw inter-
cept values by assuming condition-specific average temperature
change and subtracting the average linear effect of temperature
on intercept. A 2 2 repeated-measures ANOVA was run exactly
as before. The predicted intercept reduction of O-2545 remained
(main effect of drug on intercept, F(1,5) 9.14, p 0.043).
Confirmatory analyses: slope reduction by environmental
novelty was not a secondary consequence of changes in
cranial temperature
Because aural temperature and the slope of the theta frequency–
speed relationship were significantly correlated during baseline
(preinjection) trials in experiments 1 and 4, we checked whether
the slope reduction by environmental novelty was attributable to
lower temperatures in the novel environments. In experiment 2,
a paired t test confirmed that temperature was very similar across
Figure 10. Slope reduction by environmental novelty is not attributable to temperature
reduction (experiments 2 and4).a, Experiment 2: temperaturewas similar in the familiar (black
squares) and novel (red squares) environments. b, Experiment 4: temperature was similar
(slightly increased) in the novel environments (red square) relative to the familiar environment
(black squares).
Figure 9. Aural temperature showed no relation to intercept but was positively correlated
with slope (experiments 1 and 4). In experiment 1, temperature was measured in rats 3–6
(a–d) and was positively correlated with slope. In experiment 4, slope and temperature were
positively correlated in three of four rats: rat 3 (e), rat 5 (f ), and rat 6 (g).
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the novelty and familiarity conditions [paired t(5)  0.03, p 
0.97, average of novelty (T4 and T5) vs average of familiar (T1–T3
and T6) trials; Fig. 10a]. Accordingly, the slope reduction ob-
served during exposure to unexpected environmental novelty
was not attributable to temperature reduction. In experiment 4,
the equivalent comparison with that for experiment 2 is shown by
Figure 10b: temperature increases somewhat under unexpected
novelty on the vehicle novelty day. The mean net effect of unex-
pected novelty under vehicle was a mild increase of 0.16°C (vehi-
cle novelty T4 –T3 vs vehicle familiar T4 –T3, t(3)  0.71, p 
0.53; the mean net effect of unexpected novelty under drug was
0.04°C, n.s.]. Given the evidence from baseline trials in exper-
iment 4 (and experiment 1) that slope and temperature are pos-
itively correlated (Fig. 8), increases in temperature could only
have worked against the observed effect of novelty-elicited slope
reduction.
Confirmatory analyses: coverage of the environments cannot
explain the reduction of slope of novelty and the reduction of
intercept of anxiolytic drugs
We examined whether differential coverage of the environments
could explain the observed effects. We saw no sign of this. Re-
garding average running speed, we note that our analysis pur-
posely minimizes the effect of any consistent changes in average
running speed by analyzing samples of locomotion binned into
10 small (2.5 cm/s wide) bins and by applying both lower limits
(no samples5 cm/s) and upper limits (no samples30 cm/s).
Across-trial differences in the average speed in each bin are neg-
ligible. Nevertheless, to provide a richer characterization of the
response to novelty and anxiolytic drugs, we consider average
running speed further here.
Figure 11 depicts the effect of the first exposures to novelty on
average running speed in experiment 2 (left columns) in the first
novelty day of experiment 3 (left middle columns) and in the
novelty exposures of experiment 4 [divided into novelty under
saline (right middle columns) and novelty under drug (right col-
umns)]. There is no consistent change in
running speed. Comparing novelty probe
relative to baseline trials, average running
speed did not change in experiment 2
(paired t(5) 0.12, p 0.91, T4 vs T3 net
change, 0.19 cm/s) or in experiment 4
under O-2545 (paired t(5)  0.68, p 
0.53, T4 vs T3 net change, 0.70 cm/s),
significantly decreased in experiment 3
(paired t(4) 4.05, p 0.02, T4 vs T3 net
change,1.87 cm/s), and significantly in-
creased in experiment 4 under saline
(paired t(5) 3.00, p 0.03, T4 vs T3 net
change,4.62 cm/s). Thus, all three pos-
sible responses were seen: no change, de-
crease, and increase in average running
speed. Of course, as presented above (cf.
Figs. 4, 6) in all four conditions of envi-
ronmental novelty, the novelty consis-
tently, powerfully reduced slope. In
summary, it is implausible that changes in
average running speed can explain
novelty-elicited slope reduction.
Regarding anxiolytic drugs, CDP did
not affect average whole-trial running
speed (F(2,6)  1.29, p  0.34; mean net
effect of CDP doses vs saline1.08 cm/
s); Buspirone did reduce average whole-trial running speed
(F(2,6)  25.1, p  0.001; mean net effect of buspirone doses vs
saline, 7.22 cm/s), and O-2545 had no significant effect on
average whole-trial running speed (two-way repeated-measures
ANOVA; main effect of O-2545, F(1,5) 4.8, p 0.08; mean net
effect of O-2545 vs saline, 2.03 cm/s). Thus, for two of three
anxiolytic drugs, there was no significant reduction in running
speed.
Although it is conceivable that average running speed might
be associated with a variable that is not directly controlled for by
matching speeds across different trials and conditions and that
variable might be linked to slope or intercept, the only likely
candidate for such a mediating variable is temperature, which
tends to positively correlate with running speeds. We have al-
ready shown that variation in temperature cannot explain the
reduction of slope by novelty or the reduction of intercept by
anxiolytic drugs.
Finally, we could see no qualitative differences in paths taken
by the rats under anxiolytic drugs or in environmental novelty
(Fig. 12). Figure 12a shows examples in which rats take longer
paths under anxiolytic drugs (i.e., run faster on average) and
intercept is reduced. Figure 12b shows examples of longer and
shorter path lengths in environmental novelty, and slope is con-
sistently reduced.
Statistical power analyses: the independence of slope
and intercept
Our theoretical framework predicted, and we observed, intercept
reduction by anxiolytic drugs and slope reduction by environ-
mental novelty. Furthermore, the model by Burgess, 2008 pre-
dicts dissociability between the slope and intercept components
of theta frequency. We observed reduction of intercept without
slope reduction by anxiolytic drugs in experiments 1 and 4 and
reduction of slope without intercept reduction in environmental
novelty in experiments 2– 4, thus, a double dissociation over the
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Figure 11. Slope reduction by environmental novelty is not attributable to changes in running speed (experiments 2–4).
Environmental novelty elicited inconsistent average running speed responses. Relative to baseline trials, average running speed in
novelty probe trials (experiments 2 and 4, T4 vs T3; experiment 3, T3 vs T2) were similar (experiment 2, experiment 4 under drug),
lower (experiment 3), or higher (experiment 4 under saline). In all cases, novelty reduced slope (cf. Figs. 4, 6).
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subjects double dissociation of slope and
intercept. To what extent does this show
that the slope and intercept are truly dis-
sociable? We do not argue that anxiolytic
drugs are invariably without effect on
slope or that unexpected environmental
novelty conditions are invariably without
effect on intercept, but that the two com-
ponents are entirely dissociable in some
conditions. To investigate this issue fur-
ther, we consider effects of size, power,
and sample size to show that, in some con-
ditions, as predicted, the components are
entirely dissociable. In what follows,
power-related calculations were per-
formed using G*Power, version 3.1.3,
with 	 set to 0.05, two tailed.
Anxiolytic drugs can reduce intercept
with negligible effects on slope
We tested three drugs: CDP and buspi-
rone in experiment 1 and O-2545 in ex-
periment 4. The effect size of intercept
reduction for the low dose of CDP was
2.09, with observed power of 0.93. The ef-
fect size of intercept reduction for the low
dose of buspirone was 2.06, with observed
power of 0.92. The appropriate sample
sizes to detect these effects with minimum
power of 0.8 (in fact, the closest minimum power is 0.93 and 0.92,
respectively, i.e., the observed power) would be n  4 for CDP
and n 4 for buspirone. In clear contrast, the effect size of slope
reduction for the low dose of CDP was 0.037 (observed power of
0.06). The effect size of slope reduction for the low dose of buspi-
rone was 0.56 (observed power of 0.22). The appropriate sample
sizes to detect these effects at minimum 0.8 power would be n
4577 for CDP and n 22 for buspirone. Thus, detecting an effect
of low-dose CDP on slope would require three orders of magni-
tude more subjects than to detect an effect of the same dose of
CDP on intercept. In our view, practically speaking, this equates
to a complete (single) dissociation. The equivalent analysis on the
drug O-2545 (familiar environment vehicle vs familiar environ-
ment drug) showed that the effect size of intercept reduction by
O-2545 was 3.06 (observed power approaching unity). In clear
contrast, the effect size of slope reduction by O-2545 was 0.07
(observed power of 0.05).
The appropriate sample sizes to detect these effects at mini-
mum 0.8 power would be n 4 for intercept reduction and n
1604 for slope reduction. Thus, detecting an effect of our dose of
O-2545 on slope would require 400 more subjects than to de-
tect an effect of the same dose of O-2545 on intercept. In our
view, again, this equates to a complete (single) dissociation.
Environmental novelty can reduce slope with negligible
effects on intercept
To increase the power of our analyses, we combined the results of
experiments 2 and 4 (n  12, all electrodes in CA1, drug-free,
baseline familiar environment trial 3 vs novel environment probe
trial 4). The effect size of slope reduction by environmental nov-
elty was 2.42, with observed power approaching unity. The effect
size of intercept reduction by environmental novelty was 0.45 (ob-
served power of 0.43). The appropriate sample sizes to detect these
effects with minimum power of 0.8 would ben 3 for slope (closest
minimum power is 0.83) and n 32 for intercept. Thus, detecting
an effect of environmental novelty on intercept would require
one order of magnitude more subjects than to detect an effect
of the same novelty on slope. In our view, this equates to a
strong dissociation.
Even this low level of intercept reduction is not inevitable on
exposure to unexpected environmental novelty. Taking experi-
ment 4 on its own (n  6), the effect size of slope reduction by
environmental novelty was 2.24 (observed power of 0.99). In
clear contrast, the effect size of intercept reduction by environmental
novelty was 0.07 (observed power of 0.05). The appropriate sample
sizes to detect these effects at minimum 0.8 power would ben4 for
slope reduction (closest minimum power is 0.83) and n 1604 for
intercept reduction. Thus, detecting an effect of environmental nov-
elty on intercept would require 400more subjects than to detect an
effect of the same novelty on slope. In our view, this equates to a
complete (single) dissociation.
Together, the results show a double dissociation in which
both intercept and slope can vary independently. Experiment
4 shows this double dissociation within subjects: intercept was
reduced by a drug while negligibly affecting slope, and slope
was reduced by a novelty condition while negligibly affecting
intercept. We conclude that, although some probe conditions
will involve changes in both the intercept and slope relative to
a baseline condition, these two contributions to theta fre-
quency are entirely dissociable.
Summary
We hypothesized a dissociation between the factors affecting the
intercept and the slope of the theta frequency–running-speed
relationship seen in hippocampal theta. Using two clinically well-
established anxiolytic drugs (CDP and buspirone) and one puta-
tive anxiolytic drug (O-2545), which did indeed elicit anxiolytic
effects in our walled open-field model, we have shown that three
Figure 12. Anxiolytic drug-elicited intercept reduction and novelty-elicited slope reduction are not attributable to changes in
environmental coverage. a, Anxiolytic drugs reduce intercept even when path length increases (i.e., average speed increases). b,
Environmental novelty reduces slope regardless of changes in path length. All values shown are T4–T3 difference values. Paths
shown are cumulative path taken by rat over whole trial. There are no obvious qualitative difference in paths across baseline and
probe trials in either condition. Fam, Familiar; Nov, novel; Veh, vehicle.
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anxiolytic drugs have the common effect of reducing the in-
tercept of the frequency–speed relationship, despite their neu-
rochemical dissimilarity. In contrast, we have shown that
environmental novelty reduces the slope of the frequency–speed
relationship, which then increases as the novel environment be-
comes more familiar. The change in slope from baseline trial to
probe trial predicts changes in the average place field size of hip-
pocampal place cells and predicts changes in rearing, a novelty-
responsive behavior linked to the hippocampal response to
novelty. We also observed an unpredicted dissociation: aural
temperature (and thus presumably brain temperature) positively
correlates with slope but not intercept. We ruled out the possi-
bility that uncontrolled changes in temperature explain our find-
ings that anxiolytic drugs reduce intercept and environmental
novelty reduces slope.
Discussion
Theta frequency–speed slope: spatial representation
and novelty
The flatter frequency–speed slope in environmental novelty is a
surprising result and implies a disruption to running speed-based
hippocampal calculations of distance traveled, which will affect
models of spatial coding relating theta to spatial metrics (Burgess
et al., 2007; Geisler et al., 2007; Maurer and McNaughton, 2007;
Burgess, 2008; Jeewajee et al., 2008a; Brandon et al., 2011; Koenig
et al., 2011; Navratilova et al., 2012). Briefly, the predicted link
under the oscillatory-interference model between theta slope ()
and the spatial scale of grid cell firing patterns implies an expanded
spatial metric for novel environments. The basic idea that increasing
frequency with running speed allows the spatial representation to
remain constant despite changes in running speed (Lengyel et al.,
2003; Burgess et al., 2007) is seen in the theta-band modulation of
place (O’Keefe and Recce, 1993; Geisler et al., 2007) and grid cell
firing (Jeewajee et al., 2008a). Intuitively, the reduced slope in a novel
environment, i.e., the reduced gain in converting velocity increases
into frequency increases, suggests that the rat’s physical displace-
ment will be underestimated in the hippocampal formation. The
prediction of the model of a novelty-induced expanded metric con-
comitant with slope reduction has been observed in grid (Barry et al.,
2012) and to a lesser degree place (Karlsson and Frank, 2008; Barry et
al., 2012) cells, consistent with the consensus that grid cells provide
an important metrical input to place cells (McNaughton et al., 2006).
We now show here that changes in slope predict changes in place
field size across baseline and probe trials even when the novelty status
of the probe environment is controlled for.
What is the function of the striking reduction of slope under
novelty? Grid scale expansion should cause a mismatch between
the grid cell inputs to place cells and the environmental inputs
mediated by boundary-related cells in subiculum (Lever et al.,
2009) and entorhinal cortex (Solstad et al., 2008), which are es-
sentially unaffected by environmental novelty (Lever et al., 2009).
This mismatch could be an important trigger of the novelty-
elicited remapping of place cell representations (Burgess, 2008;
Barry et al., 2012; the present study) and a trigger for novelty-
elicited exploration. Correspondingly, the frequency of rearing, a
novelty-responsive, hippocampal-dependent, exploratory be-
havior (Lever et al., 2006), was also strongly correlated with theta
slope.
Our findings also help to clarify the hippocampal response to
novelty. We previously observed a novelty-elicited theta fre-
quency reduction (Jeewajee et al., 2008b). We now show that this
effect is driven by reduced theta slope, with interesting implica-
tions for computations of spatial scale, and this reduction is dis-
sociated from the frequency reduction with anxiolytic drugs,
which we now show corresponds to reduced theta intercept in
freely moving rats. These findings were predicted previously
(Burgess, 2008) but may also be consistent with other models
(Navratilova et al., 2012). We have also observed a later theta
phase of firing in CA1 place cells in novelty (Lever et al., 2010),
consistent with models of encoding-retrieval dynamics within
the theta rhythm (Hasselmo et al., 2002).
Theta intercept, anxiolysis, and immobility theta
It is well established that a neurochemically wide range of anxio-
lytic drugs reduce the frequency of reticular-elicited hippocam-
pal theta in the anesthetized rat (for review, see McNaughton et
al., 2007; Engin et al., 2008; Siok et al., 2009; Yeung et al., 2012).
Indeed, Gray and McNaughton (2000) have argued that theta-
frequency reduction remains the best preclinical (i.e., animal-
based) test for predicting a clinically efficacious anxiolytic drug.
Conversely, drugs that are antipsychotic or sedative but not an-
xiolytic (e.g., haloperidol and chlorpromazine) do not reduce
reticular-elicited theta frequency. Currently, as an animal-based
test for efficacy in treating human generalized anxiety disorder,
the theta-frequency reduction test for anxiolytics has no false
positives and no false negatives and has predicted the anxiolysis of
several drug classes introduced since the original idea, e.g.,
5-HT1A agonists (e.g., buspirone), serotonin-reuptake inhibitors
(Munn and McNaughton, 2008), and the calcium-channel
blocker pregabalin (Siok et al., 2009).
Theta intercept is the frequency of theta during immobility, as
extrapolated from theta during movement. Theta during alert
immobility is characterized as type II as opposed to movement-
related type I theta. Accordingly, the power of immobility theta
has been shown to depend on arousal and be atropine sensitive
(Green and Arduini, 1953; Kramis et al., 1975; Sainsbury et al.,
1987). The frequency of immobility theta has been less studied. In
contrast to the low (4 – 6 Hz) theta frequencies reported in young
(Wills et al., 2010) or anesthetized (Kramis et al., 1975; Klaus-
berger et al., 2003) rats, aroused, immobile adult rats often show
higher frequencies consistent with our intercept values (e.g.,
8.8 and 8 Hz during avoidance paradigms: Bland et al., 2006,
2007; 8 Hz during fixation in nose-poke paradigms: Takahashi et
al., 2009). Our proposed identification of intercept mechanisms
with type II theta mechanisms remains to be confirmed. More-
over, although we show that anxiolytic drugs robustly reduce
intercept, we cannot currently distinguish between three possi-
bilities regarding the potential bidirectionality of anxiety and in-
tercept: (1) anxiety increases intercept but our anxiety paradigms
were too mild to elicit this; (2) relationships between intercept
and anxiety reflect individual differences mediated by the hip-
pocampus (Oler et al., 2010) and altered by anxiolytic drugs, such
that intercept is higher in high-anxious trait rats exposed to anx-
iogenic stimuli than similarly exposed low-anxious trait rats, as
would be consistent with Meyza et al. (2009); and (3) intercept
does not increase with anxiety, with the level of intercept perhaps
reflecting a homeostatic set point that is disrupted by anxiolytic
drugs (see also point 2, above).
Here we have shown that the intercept frequency extrapolated
from freely moving rats shows the same response to anxiolytic
drugs as reticular-elicited theta in anesthetized rats. This allows
concurrent examination (e.g., during preclinical screening) of
the effects of anxiolysis on theta and behavior during classic anx-
iety tests (and potentially novel ones), in which the rodent moves
naturally (and is not anesthetized, freezing, or otherwise immo-
bile). Our experiment 4 demonstrated the feasibility of this ap-
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proach. We identified a recently introduced drug (O-2545) as a
putative anxiolytic on the basis of its CB1 receptor agonism. We
then demonstrated that it reduces anxiety-like behavior and re-
duces the intercept of the theta–speed relationship, as predicted
by our model. Thus, altogether, we refine the theta frequency–
anxiolysis relationship, expand its scope, show its specificity (nei-
ther slope nor power being affected), and extend its range beyond
drugs already known to reduce theta frequency (albeit reticular-
elicited and under anesthesia; Yeung et al., 2012).
Theta and anxiolytic drug action
There is currently no comprehensive understanding of the mech-
anisms underlying anxiolysis. One challenge here is the diversity
of initial receptor targets of anxiolytic agents, which include bar-
biturates, benzodiazepines, 5-HT1A agonists, serotonin reuptake
inhibitors, tricyclic antidepressants, ethanol, somatostatin, pre-
gabalin, phenytoin, and CB1 agonists. The diverse pathways to
anxiolysis are exemplified by comparing the benzodiazepines
with buspirone, which is not anticonvulsant, hypnotic, muscle
relaxant, or addictive, and has no known clinical effect in
common with benzodiazepines other than anxiolysis. Thus,
benzodiazepine-mediated anxiolysis is blocked by benzodiaz-
epine receptor antagonists (Menard and Treit, 1999) but not by
5-HT1A receptor antagonists (Schreiber and De Vry, 1993). Gray
and McNaughton (2000) argue that the shared effect of anxiolysis
involves the reduction of the frequency of hippocampal theta
rather than the diverse pathways leading to this effect. Accord-
ingly, in parallel to its anxiolytic effects, the ability of buspirone to
reduce theta frequency is blocked by the 5-HT1A receptor antag-
onist pindolol (Coop and McNaughton, 1991) but not by the
benzodiazepine receptor antagonist Ro 15-1788 (Zhu and Mc-
Naughton, 1991), whereas the frequency reduction effect of ben-
zodiazepines is blocked by Ro 15-1788 (Coop et al., 1992) but not
by pindolol (Zhu and McNaughton, 1994).
The dorsoventral axis of the hippocampus
We recorded theta from dorsal hippocampus, the site of anxiety-
elicited increased theta power in 5-HT1A receptor knock-out
mice (Gordon et al., 2005) and of all the studies on the theta-
frequency reduction anxiolysis model (McNaughton et al., 2007;
Engin et al., 2008; Siok et al., 2009; Yeung et al., 2012). Because
our intercept-reduction paradigm in the locomoting rat extends
this model, dorsal recording locations were the most appropriate,
and our double dissociation is strengthened by coming from a
single neural region. Nevertheless, future investigations of dorso-
ventral differences will be of interest for three reasons. First, the
dorsal hippocampus is associated with anticipatory anxiety (Gray
and McNaughton, 2000), that is, conditioned anxiety/fear (Phil-
lips and LeDoux, 1992), whereas the ventral hippocampus is as-
sociated with both conditioned and unconditioned anxiety.
Second, the dorsal hippocampus is associated with spatial mem-
ory (Moser et al., 1995) and small-scale spatial representations
(Jung et al., 1994; Kjelstrup et al., 2008; corresponding to high
frequency-speed slope under the oscillatory-interference model,
Burgess, 2008), whereas ventral hippocampus is more associated
with unconditioned anxiety (Kjelstrup et al., 2002; Bannerman et
al., 2004; Pentkowski et al., 2006; Fanselow and Dong, 2010;
McHugh et al., 2011) and large-scale spatial representation (Jung
et al., 1994; Kjelstrup et al., 2008; corresponding to low
frequency-speed slope under the oscillatory-interference model,
Burgess, 2008). Finally, movement-related theta is more promi-
nent in the dorsal hippocampus (Maurer and McNaughton,
2007; Royer et al., 2010; Hinman et al., 2011; Patel et al., 2012),
whereas ventral hippocampal theta shows an anxiety-dependent
coherence with medial–prefrontal theta (Adhikari et al., 2010).
Conclusion
Overall, these findings corroborate a two-component model of
the generation of the theta rhythm in freely moving rodents, with
specific focus on theta frequency (Burgess, 2008), extending pre-
vious work isolating type I versus type II theta (Kramis et al.,
1975; Shin et al., 2005; Korotkova et al., 2010). These findings
suggest novel ways to isolate spatial translation- and arousal/
anxiety-related theta mechanisms in behaving animals and have
wide-ranging implications for the role of hippocampal theta in
novelty detection and memory, path integration and spatial map-
ping, and anxiolytic drug action.
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